---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008680"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T19:25:50.595106+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics Interim CFO Robert Hoffman resigns effective May 14, 2025

## Summary
- Robert E. Hoffman resigned as Interim CFO effective May 14 to pursue another opportunity.
- Hoffman will remain on the Board of Directors as a Class I director.
- Company will initiate a search for a new CFO successor.

## SEC filing metadata
- accession: 0001641172-25-008680
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000164117225008680/0001641172-25-008680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000164117225008680/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008680
- JSON: https://secwatch.observer/filing/0001641172-25-008680.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008680.txt

## Key facts
- Executive change
  Robert E. Hoffman resigned as Interim Chief Financial Officer at FibroBiologics, Inc..
  - Action: resigned
  - Role: Interim Chief Financial Officer
  source text: On May 2, 2025, Mr. Robert E. Hoffman informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Interim Chief Financial Officer, effective as of the close of business on May 14, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000164117225008680/0001641172-25-008680-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.